Elad Kedar, CEO of Orasis Pharmaceuticals shares his strategy for successfully completing a Phase 2b clinical study in preparation of their phase 3 of CSF-1 drops for temporary correction of presbyopia. Jeffry Weinhuff from Visionary Ventures joins the conversation as Chairman of the Board to explain how he evaluated the Orasis technology and what VCs look for.
Interviewer:
Ehsan Sadri, MD
Managing Partner
Visionary MD Eye Laser institute
Interviewee:
Elad Kedar
CEO
Orasis Pharmaceuticals
Jeffry Weinhuff
Chairman
Orasis Pharmaceuticals
Managing Partner
Visionary Ventures